Completed PHASE3 INTERVENTIONAL 1-arm NCT00528424

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

A Phase 3, Open-Label Extension Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease

Sponsor: Endo Pharmaceuticals

Conditions Advanced Dupuytren's Disease

Interventions AA4500

Updated 7 times since 2017 Last updated: Oct 26, 2017 Started: Dec 31, 2007 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Advanced Dupuytren's Disease, this trial is completed. The trial is conducted by Endo Pharmaceuticals and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Oct 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Oct 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Endo Pharmaceuticals

Data source: Endo Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Boston, United States , Denver, United States , Erie, United States , Indianapolis, United States , Los Angeles, United States , Minneapolis, United States , New York, United States , Newton, United States , Oklahoma City, United States and 5 more locations